Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Cipla
Cipla
Activities:
Ingredients
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Donaldson's Isolere Bio launches IsoTag reagent for optimal AAV purification
The IsoTag AAV reagent can purify adeno associated viruses for research purposes, achieving up to an 85% in yield
Novo Nordisk's haemophilia A/B drug Alhemo gets positive opinion from the EMA
The subcutaneous, self-administering prophylactic can allow a patient to produce thrombin, a clotting agent, even in the presence of inhibitors
groninger showcases filling and closing solutions for OTC pharma at Pack Expo
Discover the flexcare 101 and flexfill machines designed for enhanced efficiency and flexibility in pharmaceutical production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Cipla and Kemwell announce joint venture for biosimilars
The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation
Ingredients
Cipla signs COVID-19 licensing agreement with Gilead Sciences
Indian Cipla will be permitted to manufacture US-based Gilead’s API and finished product of Remdesivir and market it in 127 countries including India and South Africa under its own brand name
Research & Development
Indian Cipla funnels $1 million into facility in Minsk
The facility will be used to localise the production of innovative solid medicines in Belarus
Finance
Cipla to step up efforts in US market
Competition heating up, with the US Food and Drug Association approving rival drugs, which could eat away at Cipla's market share in the generic business.
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Finance
Cipla to acquire two US generics companies for $550m
Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Regulatory
Boehringer Ingelheim suffers Spiriva patent blow in India
Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
Subscribe now